James Cavet

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki et al. · The Lancet Oncology · 2011 · 917 citations

Medicine, Pharmacology, Pharmacotherapy +15

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

Frits van Rhee, Raymond Wong, Nikhil C. Munshi et al. · The Lancet Oncology · 2014 · 442 citations

Life Sciences, Immunology, Internal Medicine +5

Unmet supportive care needs, psychological well‐being and quality of life in patients living with multiple myeloma and their partners

Alex Molassiotis, Barbara A. Wilson, Susan Blair et al. · Psycho-Oncology · 2010 · 242 citations · Full text

Medicine, Oncology, End-of-life Care +14

Recipient Tumor Necrosis Factor- and Interleukin-10 Gene Polymorphisms Associate With Early Mortality and Acute Graft-Versus-Host Disease Severity in HLA-Matched Sibling Bone Marrow Transplants

James Cavet, Peter G. Middleton, Miriam Segall et al. · Blood · 1999 · 238 citations

Life Sciences, Genetics, Immunology +17

Interferon-γ and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation

James Cavet, Anne M. Dickinson, Jean Norden et al. · Blood · 2001 · 235 citations · Full text

Life Sciences, Genetics, Immunology +16